Results of the development of a drug allergy gene testing system in the Chanthaburi Province network: A prototype model for driving precision medicine

Results of the development of a drug allergy gene testing system in the Chanthaburi Province network: A retrospective cross-sectional study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260702006

Enrollment

800

Registered

2026-07-02

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of Adverse Drug Reactions (ADRs) and Severe Cutaneous Adverse Reactions (SCARs) associated with HLA-B15:02, HLA-B58:01, and HLA-B*57:01 pharmacogenomic markers. SCARs, ADR, HLA

Interventions

Patients who underwent pharmacogenomic testing between 1 April 2023 and 30 April 2024, before the development of the pharmacogenomic testing network in the Chanthaburi provincial healthcare network.,

Prevention,Prevention

Pre-implementation Group ,post-implementation Group .

Eligibility

Sex/Gender

All

Age

1 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Patients who underwent pharmacogenomic testing (HLA-B15:02, HLA-B58:01, or HLA-B*57:01) at the Genomics Laboratory, Phrapokklao Hospital. , 2. Patients who received care within the Chanthaburi provincial healthcare network. , 3. Patients with complete demographic, laboratory, and clinical data available in the hospital information system and the laboratory information system. , 4. Patients tested between 1 April 2023 and 31 May 2025.

Exclusion criteria

Exclusion criteria: 1. Patients with incomplete demographic, clinical, or laboratory data. , 2. Patients with incomplete, duplicated, or unverifiable results for HLA-B15:02, HLA-B58:01, or HLA-B*57:01 testing.

Design outcomes

Primary

Measure	Time frame
Turnaround Time (TAT) for HLA-B Genotyping At final report release Number of days from specimen receipt to final report issuance	—

Secondary

Measure	Time frame
Incidence of SCARs During follow-up after medication initiation Number and percentage of SCARs cases	—

Countries

Thailand

Contacts

Public ContactChada Sartsuk

Genomics and Precision Medicine Laboratory, Phrapokklao Hospital, Chanthaburi, Thailand

cssartsuk22@gmail.com039319666

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026